Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.
Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.
Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.
Can-Fite BioPharma (NYSE: CANF) announced that its anti-cancer drug, Namodenoson, exhibits significant inhibition of pancreatic carcinoma growth, both alone and in combination with gemcitabine, the standard chemotherapy. These pre-clinical studies highlighted Namodenoson's excellent safety profile and potential effectiveness against pancreatic cancer, a disease with a bleak 11% 5-year survival rate in the U.S. The company has filed a patent application for Namodenoson aimed at treating this aggressive cancer. The global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow significantly by 2030.
Can-Fite BioPharma (NYSE American: CANF) announced definitive agreements for a registered direct offering of 1,000,000 American Depositary Shares (ADSs) at $5.50 each, expected to yield approximately $7.5 million, alongside a private placement of 363,637 ADSs at the same price. The offerings include Series A warrants with an exercise price of $6.00 and Series B warrants at $5.50. Proceeds will fund R&D and clinical trials. The closing is anticipated by January 13, 2023, and the warrants will have a term of up to 5.5 years and 20 months respectively.
Can-Fite BioPharma has submitted a market registration plan for its lead drug candidate, Piclidenoson, to the European Medicines Agency. This follows successful topline results from the Phase III COMFORT study, which showed significant improvement over placebo in treating moderate to severe psoriasis. The drug boasts a superior safety profile compared to Otezla, the leading oral psoriasis therapy. With a focus on the $26 billion psoriasis market, Can-Fite aims to position Piclidenoson as a preferred treatment.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced a change to its American Depositary Shares (ADSs) ratio, effective January 9, 2023. The new ratio will be one ADS representing 300 ordinary shares, equivalent to a one-for-ten reverse split. Existing ADS holders will exchange ten ADSs for one new ADS. There will be no changes to ordinary shares, and the new ADSs will continue trading under the symbol 'CANF'. Following this, the ADS price is expected to increase proportionally, though there's no guarantee of reaching ten times the previous price.
Can-Fite BioPharma (NYSE American: CANF) announced significant advancements in its clinical program for Namodenoson, targeting hepatocellular carcinoma (HCC). A pivotal Phase III study is now open for enrollment focusing on patients with advanced liver cancer. Notably, a CPB liver cancer patient remains cancer-free six years post-treatment with Namodenoson. Previous Phase II data indicated improved overall survival rates for CPB7 patients treated with Namodenoson compared to placebo. The FDA and EMA have granted Orphan Drug and Fast Track status for this drug.
Can-Fite BioPharma announced advancements in developing Piclidenoson, aimed at treating canine osteoarthritis, supported by its partner Vetbiolix. The canine osteoarthritis market is projected to reach
Can-Fite BioPharma Ltd. (CANF) reported financial results for the quarter ending September 30, 2022, indicating a 6.1% revenue decline to $0.61 million compared to 2021. R&D expenses dropped 21.3% to $5.31 million, primarily due to completing the Phase III Piclidenoson study. The net loss decreased to $7.15 million from $8.50 million, largely thanks to reduced expenses. Can-Fite also highlighted significant clinical developments, including the clearance of cancer in a patient treated with Namodenoson and the positive Phase III results for Piclidenoson in psoriasis.
Can-Fite BioPharma (NYSE American: CANF) announced positive results from the Phase III COMFORT study for its drug Piclidenoson, targeting psoriasis. The study showed significant efficacy, surpassing placebo and demonstrating a safety profile comparable to that of placebo and better tolerated than Otezla®. CEO Dr. Pnina Fishman will present the findings at the 6th Annual Dermatology Drug Development Summit in Boston on November 2, 2022. With over 400 adults assessed, the promising outcomes set the stage for an upcoming pivotal Phase III registration trial.
Can-Fite BioPharma has announced the initiation of a global pivotal Phase III study for Namodenoson, a treatment for advanced liver cancer, also known as hepatocellular carcinoma (HCC). A case report presented at the AASLD’s The Liver Meeting highlights a patient who achieved a complete response after five years of treatment. The pivotal study is open for patient enrollment in various countries, including Israel and the U.S. Namodenoson holds Orphan Drug and Fast Track Status in both the U.S. and Europe.
Can-Fite BioPharma is advancing its Namodenoson liver drug candidate in a Phase IIb NASH study after a successful Phase IIa trial. CEO Dr. Pnina Fishman will present at the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022. NASH represents a significant market opportunity, expected to reach $35-$40 billion by 2025. The ongoing Phase IIb trial will evaluate Namodenoson’s efficacy against placebo in 140 subjects. Namodenoson has shown promise as a treatment for NASH and hepatocellular carcinoma, achieving Orphan Drug and Fast Track Designations.
